Evidence map›Paper›PMID 32321836›Full record

ArticleG3 (Bethesda, Md.)2020

Stavroula Petridi, C Adam Middleton, Chris Ugbode, Alison Fellgett, Laura Covill, Christopher J H Elliott

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in G3 (Bethesda, Md.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Stavroula PetridiDepartment of Biology and York Biomedical Research Institute, University of York, YO1 5DD, UK.
C Adam MiddletonDepartment of Biology and York Biomedical Research Institute, University of York, YO1 5DD, UK.
Chris UgbodeDepartment of Biology and York Biomedical Research Institute, University of York, YO1 5DD, UK.ORCID 0000-0002-6023-8294
Alison FellgettDepartment of Biology and York Biomedical Research Institute, University of York, YO1 5DD, UK.
Laura CovillDepartment of Biology and York Biomedical Research Institute, University of York, YO1 5DD, UK.ORCID 0000-0002-5086-9877
Christopher J H ElliottDepartment of Biology and York Biomedical Research Institute, University of York, YO1 5DD, UK cje2@york.ac.uk.ORCID 0000-0002-5805-3645
Karolinska Institutet · SEUniversity of York · GB

Funding

Parkinson's UK H-1201Parkinson's UK K-1704
6 · The paper itself

Abstract

LRRK2 mutations cause Parkinson's, but the molecular link from increased kinase activity to pathological neurodegeneration remains undetermined. Previous

Indexed as

DrosophilaParkinson DiseaseAnimalsDopaminergic NeuronsLeucine-Rich Repeat Serine-Threonine Protein Kinase-2Mutationrab GTP-Binding ProteinsLeucine-Rich Repeat Serine-Threonine Protein Kinase-2rab GTP-Binding ProteinsDrosophila melanogasterG2019SLRRK2Parkinson’s diseaseParkinson’s UK K-1704 G-1804Rab10Rab3

Identifiers

PMID32321836
PMCPMC7263684
OpenAlexW3019578047

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.